Date:2/3/2009

1,393,496 Selling and marketing 2,125,274 2,399,227 7,250,906 6,006,598 Amortization of intangibles 211,626 209,862 633,567 632,865 3,774,118 3,868,656 12,012,296 10,787,959 Operating loss (920,820) (929,297) (1,970,027) (3,123,636) Other income (expense) Interest income 24,001 74,928 162,657 216,550 Interest expense (1,787) (6,497) (15,372) (27,141) Foreign currency exchange loss - (37,632) (731) (53,538) Other, net - 2,134 (4,687) 4,014 22,214 32,933 141,867 139,885 Loss before income taxes (898,606) (896,364) (1,828,160) (2,983,751) Income tax expense (benefit) (4,684) 4,004 33,374 141,944 Net loss $(893,922) $(900,368) $(1,861,534) $(3,125,695) Basic and diluted loss per common share $(0.06) $(0.06) $(0.12) $(0.23) Weighted average common shares outstanding: Basic and diluted 14,924,540 14,119,583 14,919,216 13,482,928 UROPLASTY, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS December 31, 2008 March 31, 2008 (unaudited) Assets Current assets: Cash and cash equivalents & short-term investments $8,562,280 $10,146,081 Accounts receivable, net 1,501,037 2,318,604 Income tax receivable 56,488 50,841 Inventories 549,653
'/>"/>

SOURCE Uroplasty, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11
Related biology technology :

1. Uroplasty to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York
2. Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007
3. Uroplasty to Host Third Quarter Conference Call on February 11
4. Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
5. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
6. Recent Reports Regarding Mercury and High Fructose Corn Syrup Flawed and Misleading
7. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
8. Sinobiopharma Reports Financial Highlights for Six-Month Period Ending November 30, 2008
9. CuraGen Reports Fourth Quarter 2008 Financial Results; Provides Milestone and Financial Guidance for First Half of 2009
10. Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results
11. Aerolase Reports Strong Sales in 2008 for Portable Aesthetic Lasers